<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This report describes the efficacy and toxicity of PAVe (procarbazine, Alkeran, vinblastine) and irradiation (RT) in the management of 159 patients with locally extensive or advanced stage <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) at Stanford University </plain></SENT>
<SENT sid="1" pm="."><plain>Patients received six courses of chemotherapy alternating with RT </plain></SENT>
<SENT sid="2" pm="."><plain>The extent of RT and the schedule of treatment varied according to the stage of disease </plain></SENT>
<SENT sid="3" pm="."><plain>About 2/3 of patients received PAVe/RT in the setting of prospective, randomized clinical trials </plain></SENT>
<SENT sid="4" pm="."><plain>The rate of complete response was 93% </plain></SENT>
<SENT sid="5" pm="."><plain>With a median follow-up of seven years (range 2-17), the 15 year actuarial freedom from progression (FFP) is 78% and overall survival is 75% </plain></SENT>
<SENT sid="6" pm="."><plain>Ten-year FFP by stage is: 80% for locally extensive stage II, 90% for stage IIIA and 70% for stage IIIB </plain></SENT>
<SENT sid="7" pm="."><plain>Excellent and equal results were attained with PAVe/RT vs. MOP(P) (mustard, Oncovin, procarbazine with or without <z:chebi fb="0" ids="8382">prednisone</z:chebi>)/RT in the randomized combined modality studies </plain></SENT>
<SENT sid="8" pm="."><plain>Progression or recurrence was documented in 30 patients and was more common in irradiated sites </plain></SENT>
<SENT sid="9" pm="."><plain>PAVe was well tolerated acutely </plain></SENT>
<SENT sid="10" pm="."><plain>There were no treatment related fatalities </plain></SENT>
<SENT sid="11" pm="."><plain>Twenty-three (14%) patients were admitted to the hospital for neutropenic <z:hpo ids='HP_0001945'>fever</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Five <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> have occurred after PAVe/RT only: one <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, one <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, one non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and two <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> including a case of <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> and an in situ <z:mp ids='MP_0002038'>carcinoma</z:mp> of the cervix </plain></SENT>
<SENT sid="13" pm="."><plain>Three patients died from <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> several years after the completion of treatment </plain></SENT>
<SENT sid="14" pm="."><plain>These mature data show that PAVe/RT is effective and well-tolerated therapy for locally extensive stage II and IIIA/B <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>